Necessity to screen and treat latent tuberculosis before ruxolitinib treatment—Ruxolitinib-associated disseminated tuberculosis: A case report and literature review

Necessity to screen and treat latent tuberculosis before ruxolitinib treatment—Ruxolitinib-associated disseminated tuberculosis: A case report and literature review

Ruxolitinib, a Janus kinase inhibitor, considerably improves symptoms of patients with polycythemia vera and primary or secondary myelofibrosis. However, its association with the development of infectious complications is a concern. Herein, we report the case of an 80-year-old man with primary myelo...

Full description

Bibliographic Details
Main Authors: Nobuyasu Hirai, Kei Kasahara, Shingo Yoshihara, Tomoko Nishimura, Keitaro Omori, Yoshihiko Ogawa, Taku Ogawa, Naokuni Hishiya, Yuki Suzuki, Hisakazu Yano, Masahide Yoshikawa, Keiichi Mikasa
Format: Article
Language:English
Published: Elsevier 2020-01-01
Series:IDCases
Subjects:
Mycobacterium tuberculosis
Prophylaxis
Ruxolitinib
Online Access:http://www.sciencedirect.com/science/article/pii/S2214250920302006

Internet

http://www.sciencedirect.com/science/article/pii/S2214250920302006

Similar Items